Orlistat: Brands, Price & Uses in Bangladesh

Orlistat is a lipase inhibitor indicated for the management of obesity as follows:

Established / FDA-approved uses

• Weight loss and weight maintenance: Orlistat is indicated for weight loss and weight maintenance when used together with a reduced-calorie, reduced-fat diet, in adults with an initial body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of other weight-related risk factors such as hypertension, type 2 diabetes, or dyslipidemia.
• Reduction of weight regain: Orlistat is also indicated to reduce the risk of weight regain after prior weight loss.

Adjunct use — combination therapy required

• Orlistat is only effective as an adjunct to a supervised, reduced-calorie, low-fat diet (approximately 30% of daily calories from fat, distributed over three main meals). It is not effective as monotherapy without dietary modification, and may be combined with a structured exercise programme for enhanced weight loss.

Pediatric/adolescent use

• Orlistat 120 mg is approved for obesity management in adolescents aged 12 to 16 years, used together with a reduced-calorie, nutritionally balanced diet, under medical supervision.

Orlistat does not treat the underlying cause of obesity; organic causes of obesity (e.g. hypothyroidism) should be excluded before starting therapy.

Adult dose

Pediatric dose

Adolescents aged 12–16 years: 120 mg three times daily with main meals, together with a nutritionally balanced, reduced-calorie diet and under medical supervision. Use in children under 12 years is not recommended — safety and efficacy have not been established.

Renal/hepatic impairment

No dedicated pharmacokinetic studies have been conducted in patients with renal or hepatic impairment; use with caution and under medical supervision in these populations, and monitor for hepatic adverse effects (see Precautions and Warnings).

Administration notes

• If a meal is occasionally missed or contains no fat, the dose of Orlistat for that meal may be omitted.
• A multivitamin supplement containing fat-soluble vitamins (A, D, E, K) should be taken once daily, at least 2 hours before or after Orlistat (for example, at bedtime), to reduce the risk of vitamin deficiency.

Adverse effects of Orlistat are predominantly gastrointestinal, related to its mechanism of blocking fat absorption, and tend to occur more frequently with higher dietary fat intake. Counseling patients on adherence to a low-fat diet reduces the frequency of these effects.

Very common (gastrointestinal, fat-malabsorption related)

• Oily spotting/discharge from the rectum
• Flatulence with discharge
• Fecal urgency
• Oily or fatty stool
• Oily evacuation
• Increased frequency of defecation
• Fecal incontinence
• Abdominal pain/discomfort

Common

• Headache
• Upper respiratory tract infection
• Nausea

Rare but serious

• Severe liver injury, including hepatocellular necrosis and acute hepatic failure (some cases fatal or requiring transplant) — seek immediate medical attention for symptoms such as loss of appetite, jaundice, dark urine, or right upper abdominal pain.
• Oxalate nephrolithiasis and oxalate nephropathy with renal failure.
• Hypersensitivity reactions, including anaphylaxis and severe skin reactions.
• Cholelithiasis (gallstones), related to the degree of weight loss.
• Pancreatitis (postmarketing reports).